Arthritis & Rheumatology最新文献

{"title":"Reply.","authors":"Ke Jin","doi":"10.1002/art.70213","DOIUrl":"10.1002/art.70213","url":null,"abstract":"","PeriodicalId":129,"journal":{"name":"Arthritis & Rheumatology","volume":" ","pages":"2397-2398"},"PeriodicalIF":9.9,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147831354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cytokine-induced NRP2 expression in rheumatoid arthritis fibroblast-like synoviocytes: comment on the article by Jin et al.","authors":"Sho Mokuda, Michinori Ishitoku, Shintaro Hirata","doi":"10.1002/art.70252","DOIUrl":"10.1002/art.70252","url":null,"abstract":"","PeriodicalId":129,"journal":{"name":"Arthritis & Rheumatology","volume":" ","pages":"2396-2397"},"PeriodicalIF":9.9,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148203533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply.","authors":"Joseph F Merola, Cynthia E Kartman, Peter Fischer, Luna Sun, Anabela Cardoso, Mark C Genovese, Alexis Ogdie","doi":"10.1002/art.70247","DOIUrl":"10.1002/art.70247","url":null,"abstract":"","PeriodicalId":129,"journal":{"name":"Arthritis & Rheumatology","volume":" ","pages":"2395-2396"},"PeriodicalIF":9.9,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13712532/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148215671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Weight, pharmacokinetics, or cytokines? A mechanistic reading of TOGETHER-PsA: comment on the article by Merola et al.","authors":"Jacopo Ciaffi, Francesco Ursini","doi":"10.1002/art.70212","DOIUrl":"10.1002/art.70212","url":null,"abstract":"","PeriodicalId":129,"journal":{"name":"Arthritis & Rheumatology","volume":" ","pages":"2394-2395"},"PeriodicalIF":9.9,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147831297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"TOGETHER-PsA and the case for precision phenotyping in psoriatic arthritis: comment on the article by Merola et al.","authors":"Francesco Caso, Luisa Costa, Raffaele Scarpa, Francesco Maione, Roberto Giacomelli, Piero Ruscitti","doi":"10.1002/art.70246","DOIUrl":"10.1002/art.70246","url":null,"abstract":"","PeriodicalId":129,"journal":{"name":"Arthritis & Rheumatology","volume":" ","pages":"2393-2394"},"PeriodicalIF":9.9,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148203515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The development and validation of a new diagnostic sonographic enthesitis score for psoriatic arthritis: Diagnostic Ultrasound Enthesitis Tool ( DUET )","authors":"Lihi Eder, Andre L. Ribeiro, Ricardo Acayaba de Toledo, Catherine Bakewell, Philippe Carron, Basant Elnady, Amir Haddad, Arthur Kavanaugh, Arnon Katz, Minna J. Kohler, Josefina Marin, Fahmeen Afgani, Nikolas Malliotis, Nam Nguyen, Adrien Nzeusseu, Ari Polachek, Ernesto Rodriguez, Marcos Rosemffet, Abha Singh, Maria S. Stoenoiu, Agnes Szentpetery, Ilaria Tinazzi, Janeth Yinh, Mu Yang, Dennis McGonagle, Richard Cook, Gurjit S. Kaeley, Sibel Z. Aydin","doi":"10.1002/art.70384","DOIUrl":"https://doi.org/10.1002/art.70384","url":null,"abstract":"Objective The Diagnostic Ultrasound Enthesitis Tool (DUET) study aimed to develop and validate a new sonographic scoring system for enthesitis to aid PsA diagnosis. Methods We prospectively enrolled patients with early PsA, psoriasis without arthritis (PsO), and non‐inflammatory musculoskeletal symptoms as controls (CTL) from 17 centers. A standardized ultrasound assessment of 16 entheseal sites was performed and images were centrally scored by three blinded readers for inflammatory and structural entheseal lesions. Using a stepwise approach with logistic regression models stratified by age, we identified optimal lesion combinations, weightings, and entheseal sites for distinguishing PsA from CTL. Age‐specific cut‐off points were selected to maintain specificity above 70%. Performance was assessed in a validation cohort of PsA and CTL. Results We included 213 PsA, 100 PsO, and 106 CTL in the discovery cohort. The final DUET score combined weighted inflammatory (hypoechogenicity + thickening + Doppler grade x 2) and structural (enthesophyte grade + erosion x 3) scores at three entheseal sites: Achilles, proximal patellar tendon insertion, and triceps. Age stratification (≤55 vs. >55 years) improved discriminative performance. In the discovery cohort, DUET achieved an AUC of 0.65, with specificity of 73‐74% and sensitivity of 47‐49%. In an external validation cohort (101 PsA, 69 CTL), specificity improved to 74‐100% with similar sensitivity (49‐52%). Sensitivity increased up to 63% in patients with tender entheses. Conclusion DUET is a novel, externally validated sonographic enthesitis score that could support the diagnostic assessment of patients with early PsA, particularly in individuals with tender entheses.","PeriodicalId":129,"journal":{"name":"Arthritis & Rheumatology","volume":"4 1","pages":""},"PeriodicalIF":13.3,"publicationDate":"2026-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149274772","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Glucagon-Like Peptide-1 Receptor Agonist Therapy Is Associated With Improvement in Psoriatic Arthritis–Related and Metabolic Outcomes: A Retrospective Analysis of Two Cohorts","authors":"Rebecca H. Haberman MD,&nbsp;Alexandra L. Rice BA,&nbsp;Kyra Chen BS,&nbsp;Uma Scher,&nbsp;Sydney Thib BS,&nbsp;Jose U. Scher MD,&nbsp;Lihi Eder MD","doi":"10.1002/art.70170","DOIUrl":"10.1002/art.70170","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>Obesity is highly prevalent in psoriatic arthritis (PsA) and is associated with worse disease outcomes. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are increasingly being used for weight loss and diabetes, but their impact on PsA outcomes remains unclear. We aimed to characterize patients with PsA initiating GLP-1RAs and assess longitudinal changes in weight, PsA activity, and cardiometabolic parameters.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We conducted a retrospective analysis of patients with PsA who initiated GLP-1RAs. PsA disease activity data and cardiometabolic parameters from clinical visits within one year before and after GLP-1RA initiation, along with demographics and comorbidities, were collected.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Forty-eight patients with a median body mass index of 34.9 were included. Significant weight loss was observed posttreatment (−6.43 kg, 95% confidence interval [CI] −9.5 to −2.0; <i>P</i> &lt; 0.0001), with 60% losing ≥5% of their baseline bodyweight. C-reactive protein levels (−1.1 mg/L; <i>P</i> = 0.002), pain scores (−1.0; <i>P</i> = 0.01), and triglyceride levels (−0.35 mmol/L; <i>P</i> = 0.02) decreased significantly. Each 1% reduction in body weight was associated with significant improvements in the Disease Activity in Psoriatic Arthritis score (β = −0.49, 95% CI −0.94 to −0.03), tender joint count (β = −0.18, 95% CI −0.32 to −0.05), EuroQol 5-domain (β = 0.0016, 95% CI 0.008–0.023), low-density lipoprotein cholesterol levels (β = −0.05, 95% CI −0.10 to −0.003), and systolic blood pressure (β = −0.67, 95% CI −1.18 to −0.15).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>In this real-world study, GLP-1RA therapy in PsA was associated with clinically meaningful weight loss and improvements in systemic inflammation, pain, and cardiometabolic markers. Improvements in psoriatic outcomes were proportional to the degree of weight loss. These findings warrant further investigation in prospective controlled studies to evaluate the role of GLP-1RAs in PsA management and comorbidities.</p>\u0000 \u0000 <div>\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure>\u0000 </div>\u0000 </section>\u0000 </div>","PeriodicalId":129,"journal":{"name":"Arthritis & Rheumatology","volume":"78 11","pages":"2274-2279"},"PeriodicalIF":9.9,"publicationDate":"2026-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147619497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Images: Characteristic nail and skeletal findings in nail-patella syndrome.","authors":"Jina Yeo, Tae Ran Ahn","doi":"10.1002/art.70385","DOIUrl":"10.1002/art.70385","url":null,"abstract":"","PeriodicalId":129,"journal":{"name":"Arthritis & Rheumatology","volume":" ","pages":""},"PeriodicalIF":9.9,"publicationDate":"2026-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149259916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combination Therapy in Participants With Active Psoriatic Arthritis Using Subcutaneous Guselkumab and Golimumab: Week 24 Results From a Phase 2a, Multicenter, Randomized, Double-Blind, Proof-of-Concept Study","authors":"Jose U. Scher MD,&nbsp;Iain B. McInnes MD, PhD,&nbsp;Enrique R. Soriano MD, MSc,&nbsp;Joseph F. Merola MD, MMSc,&nbsp;Paul Bird MD, PhD,&nbsp;Vinod Chandran MD, PhD,&nbsp;Edaire Cheng MD,&nbsp;Elena Reynoso MD,&nbsp;Warner Chen PhD,&nbsp;Maoji Li MS,&nbsp;Lianne S. Gensler MD,&nbsp;Philip J. Mease MD,&nbsp;Christopher T. Ritchlin MD, MPH","doi":"10.1002/art.70152","DOIUrl":"10.1002/art.70152","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>To assess guselkumab + golimumab combination therapy versus guselkumab monotherapy in participants with active psoriatic arthritis (PsA) and inadequate response to tumor necrosis factor inhibitors (TNFi-IR).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Adults with active TNFi-IR PsA (three or more tender/swollen joints) were randomized (2:1) to subcutaneous guselkumab (100 mg) + golimumab (50 mg) combination therapy (n = 59) or guselkumab monotherapy (n = 32) every 4 weeks through week 20. The primary endpoint was week 24 minimal disease activity (MDA) achievement. Additional endpoints included ≥20%/50%/70% improvement in American College of Rheumatology response criteria (ACR20/50/70): improvements in psoriasis, dactylitis, and enthesitis; changes in patient-reported physical function; and impact of screening C-reactive protein (CRP) on MDA/ACR50 response.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>At baseline, participants had a median of 13 tender and 8 swollen joints and psoriatic body surface area of 3%; 23% had dactylitis. At week 24, 29% and 22% of participants achieved MDA with guselkumab + golimumab combination therapy and guselkumab monotherapy, respectively (odds ratio [OR] 1.4 [90% confidence interval 0.6–3.3]; <i>P</i> = 0.557); 44% and 22% achieved ACR50 (nominal <i>P</i> = 0.034). Participants with CRP levels ≥0.3mg/dL (intended enrollment population) receiving combination therapy (n = 40; monotherapy n = 22) had greater odds of achieving MDA (OR 12.3; nominal <i>P</i> = 0.025; 32% vs 5%) and ACR50 (OR 9.6; nominal <i>P</i> = 0.003; 55% vs 14%) at week 24. Combination therapy was associated with higher ACR20 (66% vs 44%) and ACR70 (27% vs 16%) responses and greater physical function improvements than monotherapy. Improvements in psoriasis, dactylitis, and enthesitis were similar across groups. No new safety signals and no tuberculosis/opportunistic infections occurred through week 36.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Although the primary endpoint was not achieved, secondary endpoints and exploratory analyses suggest that participants with TNFi-IR PsA, particularly those with elevated CRP levels, could derive clinically meaningful benefits with guselkumab + golimumab combination therapy, with no new safety concerns, warranting further investigation.</p>\u0000 </section>\u0000 </div>","PeriodicalId":129,"journal":{"name":"Arthritis & Rheumatology","volume":"78 11","pages":"2261-2273"},"PeriodicalIF":9.9,"publicationDate":"2026-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/art.70152","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147506777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Interleukin-2 Deprived State of Regulatory T cells and Their Recovery by Low-Dose Interleukin-2 in Patients With Inflammatory Myopathies","authors":"Justus Ohmes PhD,&nbsp;Luisa R. Monne MD,&nbsp;Sara Comdühr PhD,&nbsp;Fynn Gerlach MSc,&nbsp;Hanna Grasshoff MD,&nbsp;Alexander Dübbers MD,&nbsp;Antje Müller PhD,&nbsp;Alexander Scheffold PhD,&nbsp;Gabriela Riemekasten MD,&nbsp;Reza Akbarzadeh PhD,&nbsp;Jens Y. Humrich MD","doi":"10.1002/art.70151","DOIUrl":"10.1002/art.70151","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>Regeneration and expansion of Treg by low-dose interleukin-2 (IL-2) therapy is considered a potential treatment strategy for a wide range of autoimmune diseases. To provide a pathophysiologically-based rationale for low-dose IL-2 therapy, we investigated whether reversible defects in the Treg–IL-2 axis emerge in inflammatory myopathies.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>CD4+ T cell subsets from patients with polymyositis (PM) or dermatomyositis (DM) (n = 20) and healthy controls (HC) (n = 19) and peripheral blood mononuclear cells (PBMC) from eight patients that were stimulated in vitro for 24 hours with different concentrations of recombinant human IL-2 were analyzed by multicolor flow cytometry. Messenger RNA (mRNA) expressions of <i>IL2RA</i>, <i>IL2RB</i>, <i>IL2RB</i>, <i>ENTPD1</i>, <i>IKZF2</i>, and <i>CTLA4</i> were quantified by real-time polymerase chain reaction in IL-2 stimulated PBMC (n = 6). Two patients with refractory PM/DM were treated with low-dose IL-2 therapy for eight weeks and monitored for clinical responses and changes in Treg subsets.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Frequencies of Treg expressing CD25 at high levels (CD25hi Treg) and of CXCR5+ Treg were reduced in patients with PM/DM compared with HC (<i>P</i> = 0.0052; <i>P</i> = 0.0661), particularly in active myositis (<i>P</i> = 0.0036; <i>P</i> = 0.0335). Stimulation with low doses of IL-2 selectively enhanced expression of CD25 molecules by Treg, leading to an increase in the CD25hi Treg subset (<i>P</i> &lt; 0.05) and augmented mRNA expression of several immunoregulatory molecules (<i>P</i> &lt; 0.05). Low-dose IL-2 therapy induced decreases in muscle enzymes that were accompanied by a sustained expansion of CD25+ Treg.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Our data suggest that shortage of IL-2 is pathophysiologically relevant in PM/DM. Recovery and expansion of Treg by low-dose IL-2 therapy could thus be a promising targeted treatment option.</p>\u0000 \u0000 <div>\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure>\u0000 </div>\u0000 </section>\u0000 </div>","PeriodicalId":129,"journal":{"name":"Arthritis & Rheumatology","volume":"78 11","pages":"2341-2350"},"PeriodicalIF":9.9,"publicationDate":"2026-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/art.70151","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147507617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}